North America Branded Generics Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

TABLE 1 BRAND COMPARATIVE ANALYSIS OF THE NORTH AMERICA BRANDED GENERICS MARKET

TABLE 2 PATENT LANDSCAPE

TABLE 3 NORTH AMERICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 4 NORTH AMERICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 5 NORTH AMERICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 6 NORTH AMERICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 7 NORTH AMERICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 8 NORTH AMERICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 NORTH AMERICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 10 NORTH AMERICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 NORTH AMERICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 NORTH AMERICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 13 NORTH AMERICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 NORTH AMERICA HORMONES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 15 NORTH AMERICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 16 NORTH AMERICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 17 NORTH AMERICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 18 NORTH AMERICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 19 NORTH AMERICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 20 NORTH AMERICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 NORTH AMERICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 22 NORTH AMERICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 23 NORTH AMERICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 24 NORTH AMERICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 25 NORTH AMERICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 26 NORTH AMERICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 27 NORTH AMERICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 28 NORTH AMERICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 NORTH AMERICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 NORTH AMERICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 31 NORTH AMERICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 32 NORTH AMERICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 33 NORTH AMERICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 34 NORTH AMERICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 NORTH AMERICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 NORTH AMERICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 NORTH AMERICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 NORTH AMERICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 39 NORTH AMERICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 NORTH AMERICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 NORTH AMERICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 NORTH AMERICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 43 NORTH AMERICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 44 NORTH AMERICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 45 NORTH AMERICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 46 NORTH AMERICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 47 NORTH AMERICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 48 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 49 NORTH AMERICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 50 NORTH AMERICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 NORTH AMERICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 52 NORTH AMERICA ANTI-PSYCHOTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 53 NORTH AMERICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 NORTH AMERICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 NORTH AMERICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 NORTH AMERICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 57 NORTH AMERICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 58 NORTH AMERICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 59 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 60 NORTH AMERICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 61 NORTH AMERICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 62 NORTH AMERICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 NORTH AMERICA PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 64 NORTH AMERICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 NORTH AMERICA ONCOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 66 NORTH AMERICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 NORTH AMERICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 NORTH AMERICA DIABETES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 70 NORTH AMERICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 71 NORTH AMERICA NEUROLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 72 NORTH AMERICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 NORTH AMERICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 74 NORTH AMERICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 75 NORTH AMERICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 76 NORTH AMERICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 78 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 NORTH AMERICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 80 NORTH AMERICA ORAL IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 81 NORTH AMERICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 NORTH AMERICA INJECTABLE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 83 NORTH AMERICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 84 NORTH AMERICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 85 NORTH AMERICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 87 NORTH AMERICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 88 NORTH AMERICA VALUE-ADDED BRANDED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 89 NORTH AMERICA TRADE NAMED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 90 NORTH AMERICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 91 NORTH AMERICA ADULT IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 92 NORTH AMERICA GERIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 93 NORTH AMERICA PEDIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 94 NORTH AMERICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 95 NORTH AMERICA HOSPITALS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 96 NORTH AMERICA CLINICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 97 NORTH AMERICA HOMECARE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 98 NORTH AMERICA ACADEMIC & RESEARCH INSTITUTES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 99 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 100 NORTH AMERICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 101 NORTH AMERICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 102 NORTH AMERICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 NORTH AMERICA HOSPITAL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 104 NORTH AMERICA DIRECT TENDERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 105 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 106 NORTH AMERICA BRANDED GENERICS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 107 NORTH AMERICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 108 NORTH AMERICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 NORTH AMERICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 NORTH AMERICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 NORTH AMERICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 NORTH AMERICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 NORTH AMERICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 NORTH AMERICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 NORTH AMERICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 NORTH AMERICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 NORTH AMERICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 NORTH AMERICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 NORTH AMERICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 NORTH AMERICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 NORTH AMERICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 NORTH AMERICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 NORTH AMERICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 NORTH AMERICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 NORTH AMERICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 NORTH AMERICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 NORTH AMERICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 NORTH AMERICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 NORTH AMERICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 NORTH AMERICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 131 NORTH AMERICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 NORTH AMERICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 133 NORTH AMERICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 NORTH AMERICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 NORTH AMERICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 NORTH AMERICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 NORTH AMERICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 NORTH AMERICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 NORTH AMERICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 NORTH AMERICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 NORTH AMERICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 NORTH AMERICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 NORTH AMERICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 144 NORTH AMERICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 145 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 NORTH AMERICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 NORTH AMERICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 NORTH AMERICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 149 NORTH AMERICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 NORTH AMERICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 NORTH AMERICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 NORTH AMERICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 NORTH AMERICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 NORTH AMERICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 NORTH AMERICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 156 NORTH AMERICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 NORTH AMERICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 NORTH AMERICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 NORTH AMERICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 160 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 NORTH AMERICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 NORTH AMERICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 NORTH AMERICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 NORTH AMERICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 NORTH AMERICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 NORTH AMERICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 167 NORTH AMERICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 NORTH AMERICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 NORTH AMERICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 NORTH AMERICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 171 NORTH AMERICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 172 NORTH AMERICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 173 NORTH AMERICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 174 NORTH AMERICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 U.S. BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 176 U.S. ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 U.S. DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 U.S. ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 U.S. ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 180 U.S. BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 U.S. CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 U.S. DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 U.S. ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 U.S. CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 U.S. HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 U.S. STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 187 U.S. SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 U.S. ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 U.S. PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 U.S. ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 U.S. THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 U.S. OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 U.S. ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 U.S. PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 U.S. PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 U.S. FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 U.S. LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 U.S. STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 199 U.S. COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 U.S. FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 U.S. BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 U.S. PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 U.S. ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 U.S. ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 U.S. NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 U.S. NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 U.S. ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 U.S. TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 U.S. ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 U.S. ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 U.S. SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 U.S. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 213 U.S. TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 214 U.S. ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 U.S. MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 U.S. NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 U.S. ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 U.S. SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 U.S. FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 U.S. PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 U.S. THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 U.S. NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 U.S. BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 224 U.S. CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 U.S. PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 U.S. ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 U.S. SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 U.S. HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 U.S. DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 U.S. NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 231 U.S. GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 U.S. DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 U.S. OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 U.S. BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 235 U.S. ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 236 U.S. INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 U.S. TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 238 U.S. BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 239 U.S. BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 240 U.S. BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 241 U.S. BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 242 U.S. RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 CANADA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 244 CANADA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 245 CANADA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 CANADA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 CANADA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 CANADA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 249 CANADA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 CANADA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 CANADA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 CANADA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 CANADA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 CANADA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 CANADA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 CANADA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 CANADA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 CANADA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 CANADA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 262

TABLE 261 CANADA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 CANADA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 263 CANADA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 264 CANADA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 CANADA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 CANADA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 CANADA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 CANADA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 CANADA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 CANADA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 CANADA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 CANADA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 CANADA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 CANADA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 CANADA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 CANADA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 CANADA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 278 CANADA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 CANADA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 CANADA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 CANADA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 CANADA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 CANADA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 CANADA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 CANADA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 286 CANADA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 CANADA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 288 CANADA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 289 CANADA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 CANADA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 291 CANADA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 292 CANADA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 293 CANADA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 CANADA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 CANADA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 CANADA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 297 CANADA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 CANADA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 CANADA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 CANADA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 CANADA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 CANADA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 303 CANADA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 304 CANADA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 CANADA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 CANADA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 CANADA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 CANADA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 309 CANADA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 310 CANADA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 311 CANADA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 MEXICO BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)

TABLE 313 MEXICO ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 MEXICO DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 315 MEXICO ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 MEXICO ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 MEXICO BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 318 MEXICO CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 MEXICO DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 MEXICO ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 MEXICO CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 MEXICO HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 MEXICO STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 MEXICO SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 MEXICO ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 MEXICO PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 MEXICO ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 MEXICO THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 MEXICO OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 MEXICO ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 MEXICO PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 MEXICO PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 MEXICO FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 MEXICO LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 MEXICO STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 336 MEXICO COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 MEXICO FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 338 MEXICO BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 MEXICO PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 MEXICO ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 341 MEXICO ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 342 MEXICO NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 MEXICO NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 344 MEXICO ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 MEXICO TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 MEXICO ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 MEXICO ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 MEXICO SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 349 MEXICO SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 MEXICO TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 MEXICO ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 MEXICO MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 MEXICO NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 MEXICO ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 MEXICO SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 MEXICO FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 MEXICO PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 MEXICO THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 MEXICO NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 MEXICO BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 361 MEXICO CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 MEXICO PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 363 MEXICO ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 MEXICO SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 MEXICO HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 MEXICO DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 MEXICO NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 MEXICO GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 MEXICO DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 MEXICO OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 371 MEXICO BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)

TABLE 372 MEXICO ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 MEXICO INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 MEXICO TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 MEXICO BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 MEXICO BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)

TABLE 377 MEXICO BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 378 MEXICO BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 379 MEXICO RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)